Autopsy report · NCT04310397

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

“Study stopped due to slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 3 years 8 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Interventions

Dabrafenib; Spartalizumab; Therapeutic Conventional Surgery; Trametinib

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
  “Study was discontinued due to slow enrollment” (91% match in meaning)
• Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
  “The study was halted because enrollment was too slow” (91% match in meaning)
• Memantine and Antipsychotics Use
  “Study terminated due to too slow enrollment” (89% match in meaning)
• T2 FSL2 Weight Loss
  “Slow enrollment and Study no longer required” (88% match in meaning)
• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
  “Study closed due to slow enrollment.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.